How Long Can You Be on Dialysis? Factors & Life Expectancy

There is no fixed time limit on dialysis. Some people remain on it for decades, while others survive only months. The range is enormous because survival depends less on dialysis itself and more on the person receiving it: their age, what caused their kidney failure, their cardiovascular health, nutritional status, and the type of dialysis they use. Median survival figures vary widely, but understanding what drives those numbers can help you make sense of what to expect.

What the Survival Numbers Actually Look Like

Population-level statistics on dialysis survival can feel bleak, but they hide a lot of variation. One large study found that one-year survival on dialysis was about 80% for patients whose kidney failure was not caused by diabetes, dropping to about 73% for those with diabetic kidney disease.¹ Survival drops steeply with age: among non-diabetic patients, one-year survival was above 95% for those aged 15 to 24 but only about 53% for those over 85.

Looking further out, a study of peritoneal dialysis patients found five-year survival of 73% in younger patients versus 30% in elderly patients.² A Korean registry analysis estimated that a 30-year-old starting hemodialysis could expect to live to about age 61, while a 60-year-old could expect to reach roughly 73.³ Women tended to live slightly longer than men at similar starting ages.

These averages mask the fact that some patients do very well for very long stretches. A clinical profile of patients who had been on kidney replacement therapy for 20 years or more found that they were generally younger when they started (average age around 51), and many had received a kidney transplant at some point during those two decades. They carried a heavy burden of complications, with vascular disease and bone disease being nearly universal, but most maintained reasonable day-to-day function and about two-thirds were well nourished.⁴ The combination of cardiovascular problems, bone disease, and vision loss in these long-term survivors suggested a pattern of premature aging, but the fact that they were alive and functioning after two decades shows that dialysis is not inherently a short-term proposition.

Age at the Start of Dialysis

Age is the single strongest predictor of how long someone will survive on dialysis, more powerful than almost any other variable. This is partly because older patients are more likely to have other health problems stacked on top of kidney failure, and partly because the body’s ability to tolerate the physiological stress of dialysis declines with age. In a large UK study comparing dialysis to conservative management in elderly patients, median survival on dialysis was about 67 months for those aged 75 or younger but dropped to roughly 29 months for those older than 75.⁵ High comorbidity cut survival even further, to about 25 months regardless of treatment approach.

For younger people, the picture is different. Those who start dialysis in their twenties or thirties have decades of potential survival ahead of them, though their life expectancy remains shorter than that of age-matched peers in the general population. The gap is real but far less dramatic than the grim averages often quoted in headlines, which are pulled down by the large number of elderly, multiply-ill patients who begin dialysis late in the course of several diseases at once.

Why the Underlying Cause of Kidney Failure Matters

Not all kidney failure is the same, and the disease that destroyed the kidneys keeps affecting survival long after dialysis begins. Diabetes is the clearest example. Patients whose kidney failure was caused by diabetic kidney disease consistently have shorter survival than those with other causes.³ In the UK elderly cohort, patients with diabetes survived a median of about 45 months on dialysis, compared with 64 months for non-diabetic patients.⁵ The reason is straightforward: diabetes damages blood vessels throughout the body, not just in the kidneys. Dialysis can replace some of what the kidneys do, but it cannot undo the cardiovascular damage diabetes has already caused.

Patients whose kidney failure stems from glomerulonephritis or hypertension-related kidney disease tend to fare better, though they are not immune to cardiovascular complications. In the Chinese peritoneal dialysis study, diabetes was an independent predictor of death, roughly doubling the risk compared to patients without it.²

Cardiovascular Disease on Dialysis

Heart and blood-vessel disease is the leading killer of dialysis patients, accounting for more deaths than infections, cancer, or any other cause. The risk is staggering: cardiovascular death rates in people on hemodialysis are roughly 20 times higher than in the general population.⁶ Most people on long-term hemodialysis already have some form of cardiovascular disease by the time they start treatment.

The reasons go beyond the usual risk factors. Dialysis patients develop vascular calcification, where calcium and phosphorus deposits harden the walls of arteries and heart valves. This process is driven partly by disrupted mineral metabolism, a hallmark of advanced kidney disease. Over time, calcified vessels become stiff, raising blood pressure, reducing blood flow to the heart muscle, and increasing the risk of sudden cardiac death and stroke.⁷ Left ventricular hypertrophy, where the heart wall thickens from years of working against stiff arteries and fluid overload, is extremely common and is itself a major risk factor for dying.

Managing cardiovascular risk is one of the most consequential things a dialysis patient can do to extend survival. That means controlling blood pressure, keeping phosphorus and calcium in a reasonable range, managing fluid between sessions, and staying physically active when possible.

Hemodialysis Versus Peritoneal Dialysis

The two main forms of dialysis are hemodialysis, which filters blood through a machine, and peritoneal dialysis, which uses the lining of the abdomen as a natural filter. Whether one is better for survival has been debated for decades, and the honest answer is: it depends on who you are and how long you have been on treatment.

In the first couple of years, peritoneal dialysis appears to have a survival edge. A propensity-matched study found that peritoneal dialysis patients had about 8% lower overall mortality risk than hemodialysis patients from the start of treatment. At one year, survival was about 86% for peritoneal dialysis versus 81% for hemodialysis, and the gap persisted at two years. However, by three and four years, the difference had essentially vanished.⁸ This early advantage was strongest in patients under 65, those without diabetes, and those without cardiovascular disease. Another analysis found an even larger early benefit, estimating peritoneal dialysis was associated with roughly half the mortality risk of hemodialysis during the first two years.⁹

For older adults, the picture reverses over time. A meta-analysis focused on elderly patients found that peritoneal dialysis carried about a 17% higher mortality rate than hemodialysis overall, with the disadvantage concentrated in patients with diabetes, those with multiple comorbidities, and those on dialysis for more than three years.¹⁰ One possible reason is that peritoneal membrane function deteriorates over years of use, reducing the effectiveness of dialysis. A serious complication called encapsulating peritoneal sclerosis, where the membrane scars and traps the intestines, becomes increasingly likely the longer someone uses peritoneal dialysis. The risk rises from about 2% after five years to nearly 20% after eight or more years.¹¹

Home Dialysis Versus In-Center Treatment

Several observational studies have found that patients who dialyze at home, whether hemodialysis or peritoneal dialysis, tend to live longer than those treated in dialysis centers. A French propensity-matched analysis found that the death rate after two years was about 10% for in-center hemodialysis patients versus roughly 2% for daily home hemodialysis patients.¹² Those are striking numbers, but they come with a major caveat.

The patients who end up doing home dialysis tend to be younger, healthier, more motivated, and more likely to have strong social support. It is genuinely unclear whether the survival advantage comes from the home setting itself or from the fact that the kind of person who can manage daily home treatments is already a lower-risk patient.¹³ Home hemodialysis also tends to involve more frequent sessions, which may deliver better toxin clearance and fluid management than the standard three-times-a-week in-center schedule. Disentangling the effects of patient selection from the effects of the treatment itself has proven difficult.

Vascular Access and Its Surprising Impact

For hemodialysis patients, the type of vascular access used to connect the body to the dialysis machine has a surprisingly large association with survival. The three main types are an arteriovenous fistula (a surgically created connection between an artery and vein, usually in the arm), an arteriovenous graft (a synthetic tube connecting artery to vein), and a central venous catheter (a tube placed in a large vein in the neck or chest).

A seven-year cohort study found dramatic differences. Two-year survival was about 94% for patients using a fistula, 70% for those with a tunneled catheter, and only 37% for those with a non-tunneled catheter. At seven years, the gap widened further: 66% survival for fistula users versus 26% for tunneled catheters and 11% for non-tunneled catheters.¹⁴ Catheters carry higher infection risk and are associated with more inflammation, both of which contribute to worse outcomes.

However, the story is not as simple as “fistulas save lives.” A thoughtful analysis of US data found that patients who had a fistula attempt but ended up starting with a catheter anyway still had substantially lower mortality than patients who started with a catheter without ever trying for a fistula. This suggests that at least two-thirds of the apparent survival benefit of fistulas is explained by patient factors, meaning that the healthier patients who can tolerate fistula surgery and have suitable blood vessels are also the ones who would have lived longer regardless.¹⁵ Still, avoiding long-term catheter use when possible remains a standard recommendation.

Residual Kidney Function and Nutrition

Two factors that fly under the radar in public conversations about dialysis survival are residual kidney function and nutritional status.

Even after the kidneys have failed badly enough to need dialysis, they are rarely producing zero output. The small amount of urine the kidneys still make, and the toxin clearance and fluid removal that come with it, is called residual kidney function. Preserving it has been linked to better survival and quality of life in both hemodialysis and peritoneal dialysis patients.¹⁶ Peritoneal dialysis tends to preserve residual kidney function longer than hemodialysis, which is one explanation for its early survival advantage. Certain medications (particularly a class of blood-pressure drugs) may help maintain residual function, while nephrotoxic drugs and excessive fluid removal during dialysis sessions can accelerate its loss.

Nutritional status, particularly protein levels, is one of the strongest predictors of how long a dialysis patient will live. Low serum albumin, a protein in the blood that reflects both nutritional intake and inflammation, is a powerful harbinger of poor outcomes. In the US Renal Data System, each one-gram-per-deciliter drop in albumin was linked to a 39% increase in cardiovascular death risk.¹⁷ The condition known as protein-energy wasting, where dialysis patients progressively lose muscle and fat stores, is common and deadly. It is driven by a combination of poor appetite, chronic inflammation, nutrient losses during dialysis, and dietary restrictions that can be overly strict.¹⁸ Keeping weight and protein levels up, often with the help of a renal dietitian, is one of the most practical things a dialysis patient can do.

Exercise During Dialysis

Physical activity is an underused tool in dialysis care. Frailty is extremely common in dialysis patients, and it predicts faster decline and earlier death. A growing body of research suggests that exercising during dialysis sessions, known as intradialytic exercise, can push back against this.

A randomized trial found that patients who exercised during their dialysis sessions had 94% survival at one year compared with 73% in the control group.¹⁹ That is a single trial and the effect size is large enough to warrant caution in interpreting it, but it aligns with broader evidence. A meta-analysis found that intradialytic exercise reduced frailty scores and fatigue, while increasing grip strength and walking distance.²⁰ A larger multicenter trial showed clear improvements in physical function and fewer hospital days, though it did not find a statistically significant difference in mortality over 12 months.²¹ Even without a proven mortality benefit in every trial, the improvements in physical function, reduced hospitalization, and lower frailty are meaningful in their own right.

Transplantation as a Way Off Dialysis

A kidney transplant, when it is an option, offers the clearest path to living longer. A study of people over 70 found that beyond the first nine months (during which surgical risk is highest), transplant recipients had 38% lower mortality than matched dialysis patients, with five-year survival of 80% versus 53%.²² A broader analysis confirmed that transplant was associated with increased survival across all adult ages compared with continuing dialysis and remaining on the waiting list over a ten-year follow-up.²³ Even for patients with comorbidities like cardiovascular disease, getting on the transplant waiting list was associated with additional years of life compared with staying on dialysis.²⁴

Not everyone is eligible. People with advanced heart failure, active cancer, or severe frailty may not survive the surgery. Organ shortages mean that wait times stretch into years in many regions, during which time on dialysis accumulates its own toll. But for those who are candidates, pursuing transplant evaluation early rather than later is one of the clearest survival-improving decisions available.

Depression, Adherence, and Socioeconomic Factors

Survival on dialysis is not purely a medical equation. Depression is common among dialysis patients, and it predicts earlier death. One study found that severe depressive symptoms were significantly associated with shorter time to death even after controlling for age, illness severity, and diabetes status.²⁵ Medication nonadherence was also independently linked to higher mortality risk. Depression, reduced function, and poor adherence tend to feed on each other: depression saps energy, which reduces physical activity and engagement with treatment, which worsens health, which deepens depression.

Socioeconomic factors cast a long shadow. A meta-analysis found that lower income was associated with higher mortality in both hemodialysis and peritoneal dialysis patients.²⁶ For peritoneal dialysis patients, lower education and lower-status occupations were also linked to worse survival. In the United States, neighborhood-level poverty amplifies racial disparities. Among young adult dialysis patients in low-income neighborhoods, Black patients had roughly 46% higher mortality than white patients in the same neighborhoods after adjusting for comorbidities. That disparity largely disappeared in higher-income neighborhoods.²⁷ Transportation barriers, food insecurity, limited access to nephrologists, and stress all contribute to these patterns.

When Dialysis May Not Be Worth Starting

For some elderly patients with multiple serious health problems, dialysis may extend life by only weeks or months while significantly increasing time spent in hospitals and on treatment. A review of the evidence found that dialysis primarily prolonged survival in younger and less comorbid patients, and the advantage diminished sharply with increasing frailty. Conservative kidney management, which focuses on symptom control and quality of life without dialysis, was associated with comparable or even better quality of life and fewer hospitalizations in these populations.²⁸ In the UK elderly study, the survival advantage of dialysis over conservative management evaporated in patients over 75 with high comorbidity burdens.⁵

This does not mean elderly patients should not start dialysis. Many older patients do well for years. But the decision should be a genuine conversation about goals, not an automatic default to treatment. If the primary goal is quality of remaining life rather than maximum duration, conservative management deserves serious consideration in frail, elderly patients with multiple comorbidities.

Long-Term Complications That Accumulate

The longer someone stays on dialysis, the more likely they are to develop complications that are specific to the treatment itself rather than to kidney failure. One of the most characteristic is dialysis-related amyloidosis, caused by the buildup of a protein called beta-2 microglobulin that healthy kidneys normally clear from the blood. Dialysis machines remove it poorly compared to a functioning kidney, so it gradually accumulates and deposits in joints and bones.²⁹ This leads to carpal tunnel syndrome, chronic joint pain, and destructive bone cysts, primarily in patients who have been on dialysis for many years.³⁰ Older age at the start of dialysis and longer time on treatment are the two main risk factors.

Newer dialysis membranes have improved the removal of middle-sized molecules like beta-2 microglobulin. Medium cut-off membranes, a relatively recent development, clear these toxins more effectively than older high-flux membranes and approach the performance of more complex techniques like hemodiafiltration.³¹ A randomized trial confirmed that these newer membranes maintained middle-molecule levels similarly to hemodiafiltration, making them a practical alternative for patients who cannot access more sophisticated setups.³² Whether this translates into fewer amyloidosis cases and longer survival over the coming decades is an open question, but the trajectory of the technology is encouraging.